After Hours Decliner
INKT Mink Therapeutics13.51+3.06+29.3%
After Hours:11.47-2.04 (-15.1%)
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
Globe NewswireTue, 10-Mar 5:30 AM
Premarket Decliner
INKT Mink Therapeutics17.50+3.30+23.2%
Premarket:14.80-2.70 (-15.4%)
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
Globe NewswireThu, 14-Aug 7:30 AM
